Ashling Wahner

Read a refresh of the top FDA news in breast cancer from April 2026, including an ODAC decision and a breakthrough device designation.

Alan L. Ho, MD, PhD, discusses the unique elements of Oz-V that may contribute to its efficacy and tolerability in OPSCC.

Oncology experts share perspectives and suggest advice for reducing burnout related to conference attendance and taking personal time away from the clinic.

Rena D. Callahan, MD, discusses questions regarding treatment sequencing with CDK4/6 inhibitors and ADCs in hormone receptor–positive breast cancer.

Frontline treatment with zovegalisib, atirmociclib, and fulvestrant yielded responses in pretreated, PI3Kα-mutated HR-positive metastatic breast cancer.

Breast cancer experts discuss nuances of using CDK4/6 inhibitors to treat patients with high-risk hormone receptor–positive, HER2-negative early disease.

Rena D. Callahan, MD, discusses clinical considerations for CDK4/6 inhibitor–based regimens and oral SERDs in hormone receptor–positive breast cancer.

Tovorafenib has received conditional marketing authorization in Europe for patients at least 6 months of age with BRAF-positive relapsed/refractory pLGG.

Post-treatment ctDNA positivity was associated with disease recurrence in locoregionally advanced HNSCC, including p16-positive oropharynx cancer.

Molecular testing identified actionable alterations in high proportions of patients with breast and colorectal cancers, regardless of ctDNA status.

Experts from across oncology specialties highlight research being presented at the 2026 AACR Annual Meeting.

With burnout and conference attendance prevalent across the oncology community, oncology professionals strive to enact positive changes.

During a recent Peer Exchange, breast and lung cancer experts discussed comprehensive strategies for identifying and mitigating the AEs associated with ADCs.

The NCCN updated its 2026 Guidelines for breast cancer screening and diagnosis to include an AI-based risk assessment tool to predict breast cancer risk.

Frontline darovasertib plus crizotinib generated a PFS improvement vs treatment of investigator’s choice in HLA-A*02:01–negative metastatic uveal melanoma.

Treatment with daraxonrasib led to PFS and OS benefits vs SOC cytotoxic chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma.

The FDA issued a CRL to RP1 plus nivolumab for the management of advanced melanoma after progression on an anti–PD-1–containing regimen.

An NDA seeking the approval of TLX101-Px for characterizing treatment-related changes in recurrent or progressive glioma has been accepted by the FDA.

Manish Patel, DO, discusses early evidence suggesting that AR inhibition may enhance the efficacy of immunotherapy in salivary gland cancer.

ASCO has published updates to the clinical practice guidelines for the use of systemic therapy across subsets of patients with thyroid cancer.

A BLA has been accepted in China seeking the approval of second-line trastuzumab pamirtecan for unresectable or metastatic HER2-positive breast cancer.

Frontline tislelizumab/chemotherapy yielded sustained PFS outcomes and a meaningful OS improvement vs placebo/chemotherapy in recurrent or metastatic NPC.

IMPT generated similar physical QOL scores, local disease control, gastronomy tube dependence, and OS vs IMRT in oropharyngeal squamous cell carcinoma.

Catch up on insights into the global development of breast cancer therapies that are making waves around the world.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in March 2026.

Neoadjuvant THP demonstrated noninferiority compared with standard TCbHP in patients with stage II or III HER2-positive breast cancer.

Read our recap of top phase 1 and 2 breast cancer data announcements and highlights that may influence further clinical research and developments.

The FDA has granted traditional approval to brexucabtagene autoleucel for the treatment of adult patients with relapsed/refractory mantle cell lymphoma.

The addition of palbociclib to maintenance HER2-directed and endocrine therapy improved PFS vs SOC therapy alone in HER2-positive advanced breast cancer.

Read a refresh of the top FDA news in breast cancer from March 2026, including anticipated approvals and a biosimilar approval.